Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

DxNA to Acquire PathoGene

Published: Monday, July 22, 2013
Last Updated: Monday, July 22, 2013
Bookmark and Share
DxNA will acquire exclusive rights for Unit Dose Platform Applications of PathoGene’s multiplexed Staphylococcus MRSA+ assay on DxNA’s Real Time PCR GeneSTAT platform.

Terms of the agreement include upfront and milestone payments as well as ongoing royalties. In addition to the License Agreement, the two companies have agreed to a Letter of Intent under which DxNA would acquire PathoGene. This transaction is expected to occur in the next 6 months, contingent on satisfactory completion of due diligence and other contingencies. Financial terms contained in the LOI were not disclosed.

Pathogene’s next generation Staphylococcus assay is clearly differentiated from current commercially available MRSA assays in that it provides rapid identification and drug resistance information for Staphylococcus infections, one of the most common hospital acquired infections. In combination with the GeneSTAT platform, this capability can be delivered to almost any healthcare setting due to its portability and “point of care” design. “In addition to testing for MRSA, Pathogene’s assay also detects multi-drug resistant Coagulase Negative Staphylococcus strains, which are actually much more common infections than MRSA. This is a significant step forward compared to current diagnostic methods and allows the assay to rapidly identify and differentiate three of the most common pathogens of hospital acquired infections – surgical site infections, medical device infections and skin and soft tissue infections – in a single multiplexed assay. This provides information to physicians in about an hour that is critical to treatment decisions that save lives, improve patient outcomes and reduce treatment costs.” said Todd Snowden, PathoGene President and CEO.

”Pathogene’s novel approach with this Staph assay provides rapid clinical answers that impact patient care, costs and outcomes making the assay an ideal complement to our GeneSTAT platform. The use of the assay for diagnostics represents a combined $650M market opportunity in the US and the EU”, said David Taus, DxNA President and CEO.

DxNA’s Real Time PCR GeneSTAT platform for molecular diagnostic infectious disease testing is uniquely postioned to meet the on-site Staph diagnostic testing needs of Hospitals, Point of Care, Long Term Care and Urgent Care Centers. The GeneSTAT analyzer with the Staph multiplexed test cartridge provides the performance, ease of use, speed, portability and economics required for Staph diagnostic testing to be broadly adopted in these clinical settings.

DxNA LLC is a privately owned Limited Liability Company located in St. George, Utah. DxNA develops and commercially manufactures molecular-based diagnostic assays formatted in a unique and proprietary test cartridge designed for analysis by its proprietary GeneSTAT® analyzer. The test cartridges, together with the GeneSTAT analyzer make up DxNA’s proprietary GeneSTAT® Platform. The current assays are both DNA- and/or RNA-based “multiplexed” tests for “real time” detection of infectious disease agents in humans, and animals or of biological contaminants in the environment. DxNA combines proprietary intellectual property with industry proven technology into the GeneSTAT Platform that the Company believes to be unique in the industry. The GeneSTAT offers unmatched simplicity and control in the processing of specimens. The Platform is comprised of an analyzer and a single-use test cartridge, and can be run with minimal training in either laboratory or field settings accepting a number of specimen types.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Imaging Software Could Speed Breast Cancer Diagnosis
Technology could improve access to diagnostic services in developing countries.
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Data Mining DNA For Polycystic Ovary Syndrome Genes
A new Northwestern Medicine genome-wide association study of PCOS – the first of its kind to focus on women of European ancestry – has provided important new insights into the underlying biology of the disorder.
Algorithm Interprets Breathing Difficulties to Aid in Medical Care
Researchers from North Carolina State University have developed an efficient algorithm that can interpret the wheezing of patients with breathing difficulties to give medical providers information about what’s happening in the lungs.
Researchers Develop qPCR Prognosis Test for NSCLC Patients
A nine-gene molecular prognostic index (MPI) for patients with early-stage non-small cell lung cancer (NSCLC) was able to provide accurate survival stratification and could potentially inform the use of adjuvant therapy in patients struggling with the disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!